Patient description: The patient is a 31-year-old woman complaining of abdominal pain. The pain started last night as diffuse abdominal discomfort. She had poor appetite as well as malaise. The pain worsened in intensity and became sharp in the morning. The pain became localized to the right lower quadrant in the morning. The temperature is within the normal limits with normal vital signs. Focal tenderness and guarding were observed during palpation of the right lower quadrant. Palpation of the left lower quadrant causes pain on the right. Her lab work is remarkable for leukocytosis. Computed Tomography of the abdomen with contrast shows the presence of a distended appendix with thickened appendiceal wall without perforation, abscess or gangrene. She is a candidate for laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Endometriosis Premenopausal women 2. The participants must have dysmenorrhea and pelvic pain associated with endometriosis. 3. The participant has experienced a regular menstrual cycle. 4. The participant has been diagnosed with endometriosis by method a), b), or c) Laparotomy Laparoscopy Chocolate cyst of the ovary confirmed by MRI  Participants diagnosed with measurable uterine fibroids with the longest diameter of 3 cm or larger 2. Participants with lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis 3. Participants with a previous or current history of thyroid dysfunction 4. Participants with current or previous history of pelvic inflammatory disease 5. Participants with positive PAP smear test result conducted 6. Participants with a history of panhysterectomy or bilateral oophorectomy 7. Participants judged by investigator to have marked abnormal uterine bleeding or anovulatory bleeding 8. Participants with a previous or current history of a malignant tumor 9. Participants who have been treated with any of the following drugs: anticoagulant drug, antiplatelet drug, tranexamic acid, selective estrogen receptor modulator (SERM), activated vitamin D, other vitamin D, calcitonin, ipriflavone, steroid hormone, vitamin K, teriparatide,or denosumab 10. Participants who have been treated with any of the following drugs: oral contraceptive and sex hormone preparation, gonadotropin-releasing hormone (GnRH) analogue, dienogest, danazol, or aromatase inhibitor 11. Participants who have been treated with bisphosphonate preparation 12. Participants with a previous or current history of hypersensitivity or allergy to Leuplin, synthetic LH-RH, LH-RH derivatives, gelatin-containing formulations or food containing gelatin, or have a previous or current history of severe hypersensitivity or severe allergy to other drugs 13. Participants with non-diagnosable abnormal genital bleeding 14. Participants with a previous or current history of osteoporosis, bone mass loss, or other metabolic bone diseases 15. Participants with clinically significant cardiovascular disease or uncontrollable hypertension 16. Participants judged by investigator to be inappropriate to participate in this study based on the 12-lead electrocardiogram (ECG) findings 17. Participants with active liver disease or jaundice, or with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin > 1.5 times the upper limit of normal (ULN) in the clinical laboratory tests